MRK Merck & Co., Inc.

NEUTRAL Impact: 2/10 DEFA14A
Horizon months Filed Apr 8, 2026 Processed 2mo ago SEC 0001193125-26-147718
Proxy solicitation materials
Latest settled — T+20d
MRK ▼ -7.39% at T+20d
NEUTRAL call ✗ call lost -7.39% · α vs SPY -14.95% · entry $122.62 → $113.56
Next anchor: T+60d in 23d
Last close $119.52 (close Jun 8) · -2.53% from $122.62 entry
Entry anchored
Apr 8, 03:59 PM ET
via Databento tick
T+1d
-0.98%
call -0.98% · α -0.91%
$121.42
settled 2mo ago
T+5d
-5.86%
call -5.86% · α -9.05%
$115.43
settled 8w ago
T+20d
-7.39%
call -7.39% · α -14.95%
$113.56
settled 5w ago
T+60d
call — · α —
in 23d

Price Chart

Loading chart...

Executive Summary

Merck's 2026 proxy statement is a routine filing for the annual shareholder meeting, proposing the election of 13 directors, an advisory vote on executive compensation, and the ratification of auditors. It also includes four shareholder proposals on ESG topics, all of which the board recommends voting against. This is standard corporate governance and does not signal any material change in the company's operations or strategy.

Actionable Insight

This is a standard, non-material filing. No immediate trading action is warranted. The board's opposition to the shareholder proposals suggests a conservative stance on ESG initiatives, which may be a point of discussion for long-term investors.

Key Facts

  • Routine proxy statement for the 2026 annual meeting.
  • Board recommends voting FOR the election of all 13 director nominees.
  • Board recommends voting FOR the advisory approval of executive compensation.
  • Board recommends voting FOR the ratification of the independent auditor.
  • Board recommends voting AGAINST four shareholder proposals on DEI risks, healthcare coverage gaps, and political contributions.

Financial Impact

No direct financial impact.

Risk Factors

  • Shareholder proposals on ESG topics could lead to future engagement or voting campaigns if support is significant.
  • Board's stance against ESG proposals may face criticism from some investor groups.

Market Snapshot

Price
$123.19
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (35 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-147718
Document: 0001193125-26-147718-index-headers.html0001193125-26-147718
Document: 0001193125-26-147718-index.html0001193125-26-147718
Document: 0001193125-26-147718.txt0001193125-26-147718
4 reports for MRK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MRK — sortable, filterable
Type Now
May 31, 2026
9d ago
ANALYST-UPGRADE
BULLISH ★ 2/10
$110.89 $110.64▼ −0.22%▼ −0.60%$119.52 (+7.79%)
May 22, 2026
18d ago
8-K
NEUTRAL ★ 3/10
$119.66 $115.68▼ −3.33%▼ −4.54%$119.52 (−0.11%)
May 1, 2026
5w ago
ANALYST-UPGRADE
BULLISH ★ 1/10
$110.89 $110.64▼ −0.22%▼ −0.60%$119.52 (+7.79%)
Apr 8, 2026
8w ago
DEFA14A
NEUTRAL ★ 2/10
$122.62 $115.43▼ −5.86%▼ −9.05%$119.52 (−2.53%)
Showing 4 of 4

US Market Status

Market Closed — Opens in 5h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access